Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (<i>FLT3</i>-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)Mark J. Levis, Kristy Burns, Jörge E. Cortes et al.|Blood|2024Cited by 5
Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With <i>FLT3</i>-ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First TrialMark J. Levis, Harry P. Erba, Pau Montesinos et al.|Blood|2024Cited by 2